CRA consultant Becky Davis recently presented “GLP-1s: Riding the Wave of Innovative Medications” at Asembia’s AXS25 Summit, which looked at the evolution of the GLP-1 category, and what might be in store for future payer management.
Why diabetes and other common health conditions matter for men on prostate cancer hormone therapy
Key takeaways Men with prostate cancer are more likely to die from heart disease, not cancer. Patients who start androgen deprivation therapy (ADT) are...

